[
  {
    "ts": null,
    "headline": "International Expansion Supports BSX Stock Amid Macroeconomic Woes",
    "summary": "BSX's Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of gastrointestinal (GI) and pulmonary treatment options.",
    "url": "https://finnhub.io/api/news?id=13bcbcd0f66f7a628b8df163e11cb4566e24d3074dc6e8790c14d9fdded31b1a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732632600,
      "headline": "International Expansion Supports BSX Stock Amid Macroeconomic Woes",
      "id": 131652378,
      "image": "https://media.zenfs.com/en/zacks.com/228e67967b066e7a755ae3614be720e1",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "BSX's Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of gastrointestinal (GI) and pulmonary treatment options.",
      "url": "https://finnhub.io/api/news?id=13bcbcd0f66f7a628b8df163e11cb4566e24d3074dc6e8790c14d9fdded31b1a"
    }
  },
  {
    "ts": null,
    "headline": "Brokers Suggest Investing in Boston Scientific (BSX): Read This Before Placing a Bet",
    "summary": "Based on the average brokerage recommendation (ABR), Boston Scientific (BSX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?",
    "url": "https://finnhub.io/api/news?id=204eb4394cb38e37a06a11d66fb15c9e36eca7b22cfece87fe740f80773e6874",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732631409,
      "headline": "Brokers Suggest Investing in Boston Scientific (BSX): Read This Before Placing a Bet",
      "id": 131653865,
      "image": "https://media.zenfs.com/en/zacks.com/ac90b3d74679f6d01a122aa033d8a9a4",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Based on the average brokerage recommendation (ABR), Boston Scientific (BSX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?",
      "url": "https://finnhub.io/api/news?id=204eb4394cb38e37a06a11d66fb15c9e36eca7b22cfece87fe740f80773e6874"
    }
  },
  {
    "ts": null,
    "headline": "BSX Stock Set to Gain From Agreement to Acquire Intera Oncology",
    "summary": "Boston Scientific's new buyout is set to expand its interventional oncology offerings.",
    "url": "https://finnhub.io/api/news?id=d47c4ab9bd5c57ce7f57cba5d035574682ea555e8a505e6d44dcfeff65a183ff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732627380,
      "headline": "BSX Stock Set to Gain From Agreement to Acquire Intera Oncology",
      "id": 131652380,
      "image": "https://media.zenfs.com/en/zacks.com/41b7bdd28f63138df08f17b665d3589a",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Boston Scientific's new buyout is set to expand its interventional oncology offerings.",
      "url": "https://finnhub.io/api/news?id=d47c4ab9bd5c57ce7f57cba5d035574682ea555e8a505e6d44dcfeff65a183ff"
    }
  },
  {
    "ts": null,
    "headline": "Invesco Health Care Fund Q3 2024 Commentary",
    "summary": "Invesco Health Care Fund underperformed its benchmark. Despite earlier signs of improving trends, our health care outlook is bearish. Read more here.",
    "url": "https://finnhub.io/api/news?id=8811a159dd6bae05dcf408a9f48cd5d03a26ef619260c992cad970093f4bc185",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732624620,
      "headline": "Invesco Health Care Fund Q3 2024 Commentary",
      "id": 131646502,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/183355336/image_183355336.jpg?io=getty-c-w1536",
      "related": "BSX",
      "source": "SeekingAlpha",
      "summary": "Invesco Health Care Fund underperformed its benchmark. Despite earlier signs of improving trends, our health care outlook is bearish. Read more here.",
      "url": "https://finnhub.io/api/news?id=8811a159dd6bae05dcf408a9f48cd5d03a26ef619260c992cad970093f4bc185"
    }
  },
  {
    "ts": null,
    "headline": "Boston Scientific to acquire Intera Oncology, terms not disclosed",
    "summary": "Boston Scientific (BSX) announced it has entered into a definitive agreement to acquire Intera Oncology, a privately held medical device company that provides the Intera 3000 Hepatic Artery Infusion Pump and floxuridine – a chemotherapy drug – both of which are approved by the U.S. FDA. The Intera 3000 pump is used to administer hepatic artery infusion therapy to treat tumors in the liver primarily caused by metastatic colorectal cancer. Boston Scientific expects to complete the transaction in t",
    "url": "https://finnhub.io/api/news?id=d3cca468c44e37c7ba0343afcc9dd58c04d047a4242f33c46af8c6ddf284d692",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732622706,
      "headline": "Boston Scientific to acquire Intera Oncology, terms not disclosed",
      "id": 131653867,
      "image": "",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Boston Scientific (BSX) announced it has entered into a definitive agreement to acquire Intera Oncology, a privately held medical device company that provides the Intera 3000 Hepatic Artery Infusion Pump and floxuridine – a chemotherapy drug – both of which are approved by the U.S. FDA. The Intera 3000 pump is used to administer hepatic artery infusion therapy to treat tumors in the liver primarily caused by metastatic colorectal cancer. Boston Scientific expects to complete the transaction in t",
      "url": "https://finnhub.io/api/news?id=d3cca468c44e37c7ba0343afcc9dd58c04d047a4242f33c46af8c6ddf284d692"
    }
  }
]